ClinicalTrials.gg
CompletedNCT00490204Updated Aug 29, 2017

Cetirizine Placebo Controlled Study For Perennial Allergic Rhinitis

A Phase 3 interventional study of Cetirizine in Rhinitis, Allergic, Perennial, sponsored by GlaxoSmithKline. Completed at 28 sites in Japan. Open to participants aged 2 Years to 14 Years. Per ClinicalTrials.gov, last updated 2017-08-29.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
239
Allocation
Randomized
Ages
2 Years to 14 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies in Rhinitis, Allergic, Perennial by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Rhinitis, Allergic, Perennial · GlaxoSmithKline.

Enrollment
13th of 25
239 · median 239
Started
2007
with 4 others
Phase 3
16 of 28
none open now
Registered
15th of 28
by date

Among the 28 studies in Rhinitis, Allergic, Perennial by GlaxoSmithKline, this one is the 13th largest by enrollment of the 25 interventional ones that give a count, is one of 5 that started in 2007, is one of 16 in phase 3, and was the 15th registered.

Rhinitis, Allergic, Perennial

178 studies on the registry are indexed under Rhinitis, Allergic, Perennial; 9 are open to participants now.

Browse Rhinitis, Allergic, Perennial studies →

Open to participants now

None of the 28 studies in Rhinitis, Allergic, Perennial by GlaxoSmithKline is open now. The open studies under Rhinitis, Allergic, Perennial, anywhere →

Who these studies take

Of the 3 Rhinitis, Allergic, Perennial studies recruiting now, none set no upper age limit and 3 stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 2 Years to 14 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 28 studies in Rhinitis, Allergic, Perennial by GlaxoSmithKline as a file.
02

Study summary

Study objective is to verify the superiority of CTZ DS to the placebo groups in the change of total nasal symptom score (TNSS) over the total treatment period from the score of the baseline assessment period.

03

Conditions studied

  • Rhinitis, Allergic, Perennial

Keywords

  • Perennial Allergic Rhinitis
  • Placebo control
  • anti-histamine
  • Cetirizine
04

Who can participate

Ages eligible
2 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • [Before the start of observation period]
  1. Children with a history of to an ingredient of cetirizine hydrochloride preparation, or hydroxyzine, cyclizine, meclozine, buclizine.

    • Children with a history of drug hypersensitivity.
    • Pregnant, lactating or possibly pregnant female children.
    • Children with complications that may be (e.g., hepatic disorder, renal disorder, heart disease or others) because of which they are judged as inappropriate for this trial.
    • Children who are sensitive to pollen as a duplicate allergen and whose treatment periods are thought in the pollen dispersion periods.
    • Children with vasomotor rhinitis and eosinophilic rhinitis.
    • Children complicated with a nasal disorder (e.g., acute or chronic rhinitis, hypertrophic rhinitis, acute or chronic sinusitis, deviation of nasal septum, nasal polyp, etc.) with a degree that may influence on the evaluation of the study drugs.
    • Children complicated with asthma that requires the treatment with adrenocortical hormone (including the preparations compounded with adrenocortical hormone).
    • Children administered the following drugs within one week (6days) or 4 weeks (27days) before the start of the observation period [within one week] • Anti-histamine drugs (oral, injection, and nasal drop) • Chemical mediator release inhibitors (mast cell stabilizer) • Th2 cytokine inhibitors (suplatast tosilate) • Leukotriene receptor antagonists • Thromboxane A2 receptor antagonists

      • Thromboxane synthetase inhibitors
      • Biological preparations and vaccines indicated against allergic rhinitis
      • Vasoconstrictor(oral and nasal drop)
      • Anticholinergic drugs (inhalant only)
      • General cold remedies (including OTC)
      • Herb medicines that have antiallergic action (SHOSEIRYUTO, SHOSAIKOTO, SAIBOKUTO, etc.)
      • OTC anti-rhinitis drugs (oral, inhalant, nasal drop) [within 4 weeks]
      • Adrenocortical hormones (oral [including combination drugs], injection, inhalant, nasal drop, suppository)
      • Histamine added γ-globulin preparations
    • Children who have started specific desensitization treatment or nonspecific modulation treatment but who have not reached the maintenance level of treatment.
    • Children who have received surgical treatment for reduction and modulation of nasal mucosa, redintegration therapy of nasal cavity to improve the degree of nasal airway, or surgical operation to improve rhinorrhea.
    • Children who have previously taken the products of this trial.
    • Children who have participated in other clinical trial within 6 months of the date of for this clinical study or children who are participating in another trial as of the date of informed consent for this trial.
    • Children judged by the investigator or sub-investigator as inappropriate to participate in the trial.

[Before the start of treatment period] - Children whose severity score calculated by the following formula on the basis of nasal symptom score (sneezing, rhinorrhea, nasal pruritus and nasal congestion) in the baseline assessment period (3 days from D5 to D7) is 10 or higher Severity of TNSS = [TDNSS(D-3)+TDNSS(D-2)+TDNSS(D-1)]/3

  • Children who have used prohibited concomitant drugs during the observation period.
  • Children who have complicated acute upper airway inflammation during the observation period.
  • Children who are applicable to the exclusion criteria as to the status [before the start of observation period] during the observation period." gher

Exclusion criteria

Exclusion criteria:

"[Before the start of observation period]

  1. Children with a history of to an ingredient of cetirizine hydrochloride preparation, or hydroxyzine, cyclizine, meclozine, buclizine.
  2. Children with a history of drug hypersensitivity.
  3. Pregnant, lactating or possibly pregnant female children.
  4. Children with complications that may be (e.g., hepatic disorder, renal disorder, heart disease or others) because of which they are judged as inappropriate for this trial.
  5. Children who are sensitive to pollen as a duplicate allergen and whose treatment periods are thought in the pollen dispersion periods.
  6. Children with vasomotor rhinitis and eosinophilic rhinitis.
  7. Children complicated with a nasal disorder (e.g., acute or chronic rhinitis, hypertrophic rhinitis, acute or chronic sinusitis, deviation of nasal septum, nasal polyp, etc.) with a degree that may influence on the evaluation of the study drugs.
  8. Children complicated with asthma that requires the treatment with adrenocortical hormone (including the preparations compounded with adrenocortical hormone).
  9. Children administered the following drugs within one week (6days) or 4 weeks (27days) before the start of the observation period [within one week]

    • Anti-histamine drugs (oral, injection, and nasal drop)
    • Chemical mediator release inhibitors (mast cell stabilizer)
    • Th2 cytokine inhibitors (suplatast tosilate)
    • Leukotriene receptor antagonists
    • Thromboxane A2 receptor antagonists
    • Thromboxane synthetase inhibitors
    • Biological preparations and vaccines indicated against allergic rhinitis
    • Vasoconstrictor(oral and nasal drop)
    • Anticholinergic drugs (inhalant only)
    • General cold remedies (including OTC)
    • Herb medicines that have antiallergic action (SHOSEIRYUTO, SHOSAIKOTO, SAIBOKUTO, etc.)
    • OTC anti-rhinitis drugs (oral, inhalant, nasal drop) [within 4 weeks]
    • Adrenocortical hormones (oral [including combination drugs], injection, inhalant, nasal drop, suppository)
    • Histamine added γ-globulin preparations
  10. Children who have started specific desensitization treatment or nonspecific modulation treatment but who have not reached the maintenance level of treatment.
  11. Children who have received surgical treatment for reduction and modulation of nasal mucosa, redintegration therapy of nasal cavity to improve the degree of nasal airway, or surgical operation to improve rhinorrhea.
  12. Children who have previously taken the products of this trial.
  13. Children who have participated in other clinical trial within 6 months of the date of for this clinical study or children who are participating in another trial as of the date of informed consent for this trial.
  14. Children judged by the investigator or sub-investigator as inappropriate to participate in the trial.

[Before the start of treatment period]

1) Children whose severity score calculated by the following formula on the basis of nasal symptom score (sneezing, rhinorrhea, nasal pruritus and nasal congestion) in the baseline assessment period (3 days from D5 to D7) is 10 or higher Severity of TNSS = [TDNSS(D-3)+TDNSS(D-2)+TDNSS(D-1)]/3 2) Children who have used prohibited concomitant drugs during the observation period.

  1. Children who have complicated acute upper airway inflammation during the observation period.
  1. Children who are applicable to the exclusion criteria as to the status [before the start of observation period] during the observation period."
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Enrollment
239 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Change in the total nasal symptom score (TNSS) during the total treatment period from the baseline

    TNSS is a sum of the nasal symptom score for sneezing, rhinorrhea, nasal congestion, and nasal itching. Each symptom is scored on a scale from 0 to 3; the range of sums for TNSS is 0 to 12. The symptoms were evaluated using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The Baseline value is defined as the average TNSS over the last 3 consecutive days prior to Day 1. For total treatment period, the average TNSS for each participant was calculated using available diary data from the total treatment period, taking the average of non-missing data during the period. Change from Baseline was calculated as the score at Baseline minus the mean score for the total treatment period.

    Time frame: From Baseline to Day 14

Secondary outcomes

  1. Changes in TNSS on the first and the second weeks of the treatment period from the baseline

    TNSS is a sum of the nasal symptom score for sneezing, rhinorrhea, nasal congestion, and nasal itching. Each symptom is scored on a scale from 0 to 3; the range of sums for TNSS is 0 to 12. The symptoms were evaluated using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The Baseline value is defined as the average TNSS over the last 3 consecutive days prior to Day 1. For total treatment period, the average TNSS for each participant was calculated using available diary data from the total treatment period, taking the average of non-missing data during the period. Change from Baseline was calculated as the score at Baseline minus the mean score at Week 1 and Week 2.

    Time frame: From Baseline to Day 7 and Day 14

  2. Mean scores for each nasal symptom and the time-course changes for the scores

    Each nasal symptom score for sneezing, rhinorrhea, nasal congestion and nasal itching is scored on a scale from 0 to 3; the larger score indicates more severe symptoms. The parent/guardian or the participant scored nasal symptoms every day.

    Time frame: From Baseline to Day 14

  3. Time-course changes in a total of daily mean nasal symptom scores (TDNSS)

    TDNSS is a sum of the daily nasal symptom score for sneezing, rhinorrhea, nasal congestion, and nasal itching. Each symptom is score on a scale from 0 to 3; the range of sums for TDNSS is 0 to 12; a larger score indicates more severe symptoms.

    Time frame: From Baseline to Day 14

  4. Investigator global improvement rating on the first day of Treatment Week 2 (Day 8) and the final observation day (Day 15 ) or at discontinuation (DC)

    The investigator evaluated the participant's improvement rating (defined as improvement in the symptoms of rhinitis compared with Baseline), using the following 5 categories: significantly improved, moderately improved, mildly improved, unchanged, and worsened.

    Time frame: Day 8 and Day 15 or DC

  5. Participant global improvement rating on the first day of Treatment Week 2 (Day 8) and the final observation day (Day 15) or at DC

    The participant's parent/guardian or the participant evaluated the participant's improvement rating (defined as improvement in the symptoms of rhinitis compared with Baseline), using the following 7 categories: significantly improved, improved, slightly improved, unchanged, slightly worsened, worsened, and significantly worsened.

    Time frame: Day 8 and Day 15 or DC

  6. Changes in each rhinoscopy finding (swelling and color of inferior conchal mucosa and aqueous secretion volume (ASV)) on first day of Treatment Week 1 (Day 1), the first day of Treatment Week 2 (Day 8) and the final observation day (Day 15) or at DC

    Rhinoscopy was assessed by the investigator by scoring swelling of inferior conchal mucosa scored as 0 (none), 1 (possible to see center of the middle turbinate), 2 (between 1 and 3), or 3 (impossible to see middle turbinate); color of inferior conchal mucosa scored as 0 (normal), 1 (pink), 2 (red), or 3 (pale); aqueous secretion volume (vol) scored as 0 (none), 1 (small amount adhered), 2 (between 1 and 3), or 3 (filled).

    Time frame: Day 1, Day 8 and Day 15 or DC

07

Study locations

28 sites
  • GSK Investigational Site
    Chiba, 277-0882, Japan
  • GSK Investigational Site
    Fukuoka, 807-0856, Japan
  • GSK Investigational Site
    Fukuoka, 811-1201, Japan
  • GSK Investigational Site
    Fukuoka, 819-0002, Japan
  • GSK Investigational Site
    Hokkaido, 001-0923, Japan
  • GSK Investigational Site
    Hokkaido, 007-0840, Japan
  • GSK Investigational Site
    Hokkaido, 053-0833, Japan
  • GSK Investigational Site
    Hokkaido, 061-1133, Japan
  • GSK Investigational Site
    Hokkaido, 061-1448, Japan
  • GSK Investigational Site
    Hokkaido, 062-0034, Japan
  • GSK Investigational Site
    Kanagawa, 212-0027, Japan
  • GSK Investigational Site
    Kanagawa, 213-0011, Japan
  • GSK Investigational Site
    Kanagawa, 216-0002, Japan
  • GSK Investigational Site
    Kanagawa, 222-0011, Japan
  • GSK Investigational Site
    Kanagawa, 224-0003, Japan
  • GSK Investigational Site
    Kanagawa, 232-0056, Japan
  • GSK Investigational Site
    Kumamoto, 862-0952, Japan
  • GSK Investigational Site
    Kumamoto, 862-0962, Japan
  • GSK Investigational Site
    Oita, 870-0021, Japan
  • GSK Investigational Site
    Saitama, 333-0861, Japan
  • GSK Investigational Site
    Saitama, 336-0022, Japan
  • GSK Investigational Site
    Saitama, 350-1205, Japan
  • GSK Investigational Site
    Saitama, 355-0062, Japan
  • GSK Investigational Site
    Shizuoka, 420-0803, Japan
  • GSK Investigational Site
    Shizuoka, 422-8066, Japan
  • GSK Investigational Site
    Shizuoka, 436-0058, Japan
  • GSK Investigational Site
    Tokyo, 157-0067, Japan
  • GSK Investigational Site
    Tokyo, 170-0005, Japan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2007 to primary completion in Oct 2007, 2 months.

Of 17 phase 3 interventional studies under Rhinitis, Allergic, Perennial, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 15. This study's 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2007
First posted
Jun 22, 2007
StartActual
Jul 27, 2007
Primary completionActual
Oct 3, 2007
CompletionActual
Oct 3, 2007
Last update
Aug 29, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00490204
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jun 22, 2007
Start date
Jul 27, 2007
Primary completion
Oct 3, 2007
Completion
Oct 3, 2007
Last update
Aug 29, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cetirizine

Start the discussion